Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07597733Active, not recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised trial of telitacicept in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: Evidence of Clinical Improvement at 24 weeks, Inflammatory Neuropathy Cause and Treatment Disability Score at 24 weeks and 4 more. Started Sep 2025; status: active, not recruiting.
02
Drugs
telitacicept
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT07597733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597733.